SCHEMBL23085273

SCHEMBL23085273

c1ccc(-c2cnc3c(c2)NCN3)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 4/20 0.49
CDK8 P49336 3/20 0.49
GSK3A P49840 3/20 0.49
CHEK1 O14757 2/20 0.49
PRKD3 O94806 2/20 0.49
MAP4K4 O95819 2/20 0.49
RET P07949 2/20 0.49
PIM1 P11309 2/20 0.49
KDR P35968 2/20 0.49
FLT3 P36888 2/20 0.49
RPS6KA3 P51812 2/20 0.49
LIMK1 P53667 2/20 0.49
CDK5 Q00535 2/20 0.49
MAP4K2 Q12851 2/20 0.49
AURKB Q96GD4 2/20 0.49
CLK4 Q9HAZ1 2/20 0.49
AURKA O14965 1/20 0.49
DAPK3 O43293 1/20 0.49
ABL1 P00519 1/20 0.49
NTRK1 P04629 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1750073 0.70 NPC1 (0.42) NPC1MAPTMEN1KMT2ANFKB1
SCHEMBL8385558 0.70 ASIC3 (0.61) GSK3BCDK8GSK3ACHEK1PRKD3
SCHEMBL17679258 0.69 HTT (0.34) GSK3BCDK8GSK3ACHEK1PRKD3
SCHEMBL5307985 0.68 NPC1 (0.46) GSK3BCDK8GSK3ACHEK1PRKD3
SCHEMBL1190583 0.67 MAP4K1 (0.47) GSK3BCDK8GSK3ACHEK1PRKD3
SCHEMBL6616746 0.67 ASIC3 (0.57) GSK3BCDK8GSK3ACHEK1PRKD3
SCHEMBL24251706 0.67 GSK3B (0.41) GSK3BCDK8GSK3ACHEK1PRKD3
SCHEMBL458916 0.66
SCHEMBL29888739 0.66
SCHEMBL21023872 0.66

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210070752-A1 HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS VIRACTA THERAPEUTICS, INC. 2021-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210070752-A1 HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS PDK1, PDK2, PDK3 GSK3B 636/4885CDK8 279/4885GSK3A 630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.